Acromegaly is a rare hormonal condition that requires careful management to reduce excess growth hormone levels, prevent complications, and improve quality of life. Treatment approaches range from surgical removal of tumors to medications and radiation therapy, with ongoing research exploring new ways to help people living with this challenging disorder.

Managing a Rare but Serious Hormonal Condition

When someone develops acromegaly, their body produces too much growth hormone, leading to changes in bones, organs, and overall health. The main goals of treatment focus on bringing growth hormone levels back to normal, reducing the size of tumors that cause the excess hormone production, relieving symptoms that affect daily life, and preventing serious complications such as heart disease, diabetes, and high blood pressure. Each person’s treatment journey is different because the condition progresses at varying rates and affects people in unique ways.^[1]

Treatment decisions depend on several factors, including how large the tumor is, how much growth hormone the body is producing, whether other pituitary hormones are affected, and the person’s overall health and age. Most people diagnosed with acromegaly are between 30 and 50 years old, though symptoms can appear at any age after puberty. Because the changes happen slowly over many years, diagnosis often comes late, sometimes seven years or more after symptoms first appear.^[7]

Medical societies and specialist groups have developed clear guidelines for what counts as successful disease control. Healthcare professionals aim to suppress growth hormone to less than 2 ng/mL during testing and to bring insulin-like growth factor 1 (IGF-1) levels back to the normal range for a person’s age. Achieving these targets can help people with acromegaly live as long as the general population, whereas untreated disease can lead to increased mortality and serious health problems.^[7]

Surgery as the Primary Treatment Approach

For most people with acromegaly, surgery offers the first and often best chance at controlling the disease. The vast majority of cases are caused by a benign tumor in the pituitary gland called a pituitary adenoma, a small growth that makes the gland produce too much growth hormone. Removing this tumor surgically can quickly reduce hormone levels and relieve pressure on surrounding brain structures, including the nerves that control vision.^[2]

The most common surgical technique is called transsphenoidal surgery, which means the surgeon reaches the pituitary gland through the nose or through a small cut above the upper teeth, behind the upper lip. This approach avoids cutting into the main part of the skull and allows direct access to the pituitary gland at the base of the brain. In many specialized centers, surgeons use fine tubes called endoscopes that are passed through the back of the nose, requiring only a small incision. The operation typically takes about 90 minutes, and most people stay in the hospital for three to five days afterward.^[9]

Surgery works best when the tumor is small. Studies show that experienced pituitary surgeons who perform 20 or more operations per year achieve better results. However, even in expert hands, surgery cures only about 60% of people with acromegaly in the long term. The success rate depends on tumor size, location, and how deeply it has grown into surrounding tissues. Some people continue to have elevated growth hormone levels after surgery, which means they need additional treatment with medication or radiation therapy.^[7][9]

After surgery, healthcare teams monitor hormone levels and perform imaging studies at least 12 weeks later to check whether any tumor tissue remains. Doctors also evaluate whether the surgery has affected the production of other pituitary hormones, which could lead to hormone deficiencies requiring replacement therapy. Long-term follow-up is essential because the disease can return, and ongoing monitoring helps catch any recurrence early.^[8]

Medication Options for Controlling Hormone Levels

Medical therapy plays an important role in acromegaly treatment, especially for people who still have elevated hormone levels after surgery or for those who cannot undergo surgery. Three main types of drugs are used, each working through different mechanisms to lower growth hormone or block its effects on the body.^[9]

Somatostatin analogues are the most widely studied and commonly used medications for acromegaly. These drugs mimic a natural hormone called somatostatin that normally puts the brakes on growth hormone production. The two main somatostatin analogues are octreotide and lanreotide. Octreotide comes in both short-acting forms that require three injections per day under the skin and long-acting forms given once a month as a deep muscle injection. Lanreotide is available as a monthly depot injection that slowly releases medication over time and can be self-administered by some patients.^[9]

These medications work by binding to specific receptors on the pituitary tumor cells, particularly receptor subtypes II and V, which inhibit the release of growth hormone. About 50 to 60% of people taking somatostatin analogues achieve growth hormone levels in the target range of less than 2 ng/mL. When people first start these medications, they may experience stomach cramping or diarrhea, but these effects usually fade within a few days. Some patients find that avoiding injections for about two hours after eating helps reduce stomach problems. In the longer term, both medications can cause gallstones, though these rarely cause symptoms or require treatment.^[8][9]

Dopamine agonists represent another medication class used to treat acromegaly. These drugs work on different receptors—dopamine receptors on the surface of tumor cells—to reduce growth hormone release through an alternative pathway. The two main dopamine agonists are cabergoline and bromocriptine, both taken by mouth rather than by injection. Cabergoline is newer, causes fewer side effects than bromocriptine, and appears more effective at lowering growth hormone and IGF-1 levels. It needs to be taken only twice weekly, making it more convenient for patients.^[9]

The newest medication approach uses a growth hormone receptor antagonist called pegvisomant. Unlike somatostatin analogues and dopamine agonists that try to reduce growth hormone production, pegvisomant works downstream by blocking the action of growth hormone at its receptors throughout the body. This prevents the liver from making too much IGF-1 in response to growth hormone signals. Pegvisomant appears remarkably effective, normalizing IGF-1 levels in almost all patients who take it. However, because it blocks hormone action rather than reducing tumor size, it does not shrink pituitary adenomas, so people taking pegvisomant may need periodic imaging to monitor tumor growth.^[8]

Medical therapy is generally reserved for people who have persistent disease after surgery. However, some patients receive somatostatin analogues as primary treatment, especially if surgery poses high risks or the tumor is difficult to remove completely. The choice of medication depends on how well each drug controls hormone levels in a particular person, how tolerable the side effects are, and practical considerations like injection frequency and cost.^[8]

Radiation Therapy for Resistant Cases

Radiation therapy is usually considered a third-line treatment for acromegaly, reserved for people whose disease does not respond adequately to surgery and medication. This approach uses targeted radiation beams to damage tumor cells gradually over time, causing them to stop producing excess growth hormone. However, radiation therapy works slowly—it may take several years for hormone levels to come down to normal ranges after treatment.^[5]

During the years between radiation treatment and achieving disease control, patients typically continue taking medications to manage their growth hormone levels. Radiation therapy also carries risks, including the possibility of damaging normal pituitary tissue, which can lead to deficiencies in other hormones that the pituitary gland produces. People who receive radiation therapy need lifelong monitoring of their pituitary function and may require hormone replacement for conditions like hypothyroidism or low cortisol levels.^[9]

Most common treatment methods

• Transsphenoidal surgery
  • Surgical removal of pituitary adenoma through the nose or upper mouth, avoiding cuts to the skull
  • Often uses endoscopic techniques with fine tubes passed through the nose
  • Most effective when tumor is small and surgeon is experienced (20+ cases yearly)
  • Cures approximately 60% of patients long-term, with better outcomes for smaller tumors
  • Hospital stay typically 3-5 days with operation lasting about 90 minutes
• Somatostatin analogues
  • Octreotide: available as short-acting (3 times daily) or long-acting (monthly) injections
  • Lanreotide: given as monthly depot injection, can be self-administered
  • Work by binding to somatostatin receptors on tumor cells to inhibit growth hormone release
  • Achieve target growth hormone levels in 50-60% of patients
  • May cause temporary stomach problems and rarely cause gallstones
• Dopamine agonists
  • Cabergoline: newer, taken twice weekly by mouth, fewer side effects
  • Bromocriptine: older medication, taken by mouth
  • Work on dopamine receptors to reduce growth hormone through alternative pathway
  • More effective at lowering growth hormone and IGF-1 than older medications
• Growth hormone receptor antagonist
  • Pegvisomant: blocks action of growth hormone at receptors throughout body
  • Normalizes IGF-1 levels in nearly all patients
  • Does not shrink tumor size, requires continued monitoring with imaging
  • Works downstream from hormone production rather than reducing secretion
• Radiation therapy
  • Reserved for cases resistant to surgery and medication
  • Uses targeted radiation beams to damage tumor cells over time
  • Takes several years for hormone levels to normalize after treatment
  • May damage normal pituitary function, requiring hormone replacement therapy
  • Patients continue medications during the years between treatment and achieving control

Promising Treatments Being Tested in Clinical Trials

While standard treatments help many people with acromegaly, researchers continue exploring new approaches to improve outcomes for those whose disease proves difficult to control. Clinical trials test innovative medications and treatment strategies that may offer better hormone control, fewer side effects, or more convenient administration compared to existing options.

Clinical trials proceed through distinct phases that answer different questions. Phase I trials test a new treatment’s safety in a small group of people, determining what doses can be given safely and what side effects might occur. Phase II trials expand to larger groups to evaluate whether the treatment actually works—in acromegaly studies, this means checking whether the experimental drug reduces growth hormone and IGF-1 levels. Phase III trials compare the new treatment directly against current standard therapies in large groups of patients, providing the evidence needed for regulatory approval if the new treatment proves beneficial.

One area of active research involves developing oral formulations of medications that currently require injections. For example, researchers are testing an oral version of octreotide that patients could take by mouth instead of receiving monthly injections. This could make treatment more convenient and improve quality of life for people who dislike injections or have difficulty accessing medical facilities for regular administration. Early studies examine whether oral formulations can achieve blood levels high enough to control growth hormone production effectively.^[9]

Scientists are also investigating new somatostatin analogues that may work better than existing medications. Some experimental drugs bind to a wider range of somatostatin receptor subtypes, which could make them more effective in tumors that don’t respond well to current somatostatin analogues that primarily target subtypes II and V. These next-generation analogues aim to control hormone levels in a higher percentage of patients while maintaining or improving tolerability.

Another research direction explores combination therapies that use two or more medications working through different mechanisms. For instance, some trials test whether combining a somatostatin analogue with pegvisomant provides better control than either drug alone. The rationale is that blocking both growth hormone production and its action at receptors might achieve superior results, especially in people whose disease resists single-drug approaches. These combination strategies require careful study to ensure they don’t increase side effects unacceptably while offering meaningful improvements in disease control.

Researchers are also studying medications that target the molecular pathways inside tumor cells that drive excessive growth hormone production. These drugs work at the cellular level to interfere with the signals that tell tumor cells to make and release growth hormone. Some experimental compounds affect specific enzymes or proteins that pituitary tumors need to function abnormally. While this research remains in early phases, it represents a fundamentally different approach that could eventually lead to treatments addressing the root causes of tumor behavior rather than just managing hormone levels.

Clinical trials for acromegaly take place at specialized medical centers around the world, including locations in Europe, the United States, and other regions. People interested in participating in clinical trials generally need to meet specific eligibility criteria, which often include having hormone levels above certain thresholds despite current treatment, having a confirmed diagnosis with imaging evidence of a pituitary adenoma, and being in generally good health aside from acromegaly. Some trials seek people who have never received treatment, while others recruit patients whose disease has not responded adequately to standard therapies.

Preliminary results from some ongoing trials have shown encouraging signs. Studies of newer somatostatin analogues have reported improvements in biochemical parameters, meaning growth hormone and IGF-1 levels decreased more effectively than with older medications. Some trials have noted positive safety profiles with side effects similar to or better than existing treatments, suggesting new medications might be as well-tolerated as current options. However, researchers emphasize that these remain early findings, and full results from completed Phase III trials are needed before any new treatment can be approved for general use.

Managing Life with Acromegaly Beyond Hormone Control

Successful acromegaly treatment involves more than just bringing hormone levels down to normal ranges. People living with this condition often need comprehensive care that addresses the various complications that can develop over years of excess growth hormone exposure. Even after achieving biochemical control, some physical changes may persist, and ongoing monitoring remains essential for maintaining long-term health.

Many people with acromegaly develop joint problems, arthritis, and carpal tunnel syndrome due to the overgrowth of bone and cartilage that occurred before diagnosis. These musculoskeletal issues may not fully resolve even when hormone levels normalize, requiring pain management, physical therapy, or surgical interventions like carpal tunnel release. Regular exercise, maintaining a healthy weight, and working with physical therapists can help manage joint symptoms and preserve mobility.

Cardiovascular complications represent another major concern. Acromegaly increases the risk of high blood pressure, abnormal heart rhythms, and structural changes to the heart muscle. After achieving hormone control, doctors monitor blood pressure regularly and may prescribe medications to protect heart health. Some people need tests like electrocardiograms or echocardiograms to assess heart function periodically. Managing cardiovascular risk factors through diet, exercise, and appropriate medications helps reduce the long-term risk of heart disease.

People with acromegaly face an increased risk of developing benign growths called polyps in their colon, which can potentially become cancerous over time. Medical guidelines recommend regular colonoscopy screening to detect and remove polyps before they cause problems. The frequency of screening depends on individual risk factors and what previous colonoscopies have found, but many people with acromegaly need colonoscopies more often than the general population.

Sleep apnea affects a large proportion of people with acromegaly due to enlarged soft tissues in the throat and changes in facial structure. This condition causes breathing to stop and start during sleep, leading to poor sleep quality, daytime fatigue, and increased cardiovascular risks. Treatment often involves using a continuous positive airway pressure (CPAP) machine at night, which keeps airways open by delivering pressurized air through a mask. Weight loss and treating the underlying acromegaly can sometimes improve sleep apnea, but many people need CPAP therapy long-term.

Diabetes and glucose metabolism problems occur frequently in acromegaly because excess growth hormone interferes with how the body processes sugar. Even after hormone levels normalize, some people continue having diabetes or prediabetes that requires ongoing management with diet modifications, oral medications, or insulin injections. Regular monitoring of blood sugar levels and hemoglobin A1c tests help guide diabetes management and reduce the risk of complications.

The emotional and psychological aspects of living with acromegaly deserve attention as well. The physical changes caused by the disease can affect self-esteem and body image, while dealing with a rare chronic condition brings its own stresses. Some people experience depression or anxiety related to their diagnosis and treatment journey. Connecting with mental health professionals, joining support groups for people with pituitary conditions, and maintaining open communication with healthcare providers about emotional well-being all contribute to better quality of life.

Special considerations apply to women with acromegaly who are pregnant or trying to conceive. Medical guidelines generally recommend discontinuing long-acting somatostatin analogues and pegvisomant about two months before attempting pregnancy, with short-acting octreotide available if needed until conception occurs. During pregnancy, medical therapy is typically used only for tumor control and headache management, as monitoring growth hormone and IGF-1 levels during pregnancy is not considered useful since these hormones naturally change during pregnancy.^[8]